BRPI0419032A - composição farmacêutica de liberação prolongada de hidralazina e seu uso como apoio para o tratamento do cáncer - Google Patents

composição farmacêutica de liberação prolongada de hidralazina e seu uso como apoio para o tratamento do cáncer

Info

Publication number
BRPI0419032A
BRPI0419032A BRPI0419032-7A BRPI0419032A BRPI0419032A BR PI0419032 A BRPI0419032 A BR PI0419032A BR PI0419032 A BRPI0419032 A BR PI0419032A BR PI0419032 A BRPI0419032 A BR PI0419032A
Authority
BR
Brazil
Prior art keywords
hydralazine
prolonged release
pharmaceutical composition
support
cancer treatment
Prior art date
Application number
BRPI0419032-7A
Other languages
English (en)
Inventor
Luis Estrada Flores
Alfonso Duenas Gonzalez
Arturo Borbolla Garcia
Raul Serna Martinez
Alfredo Rivera Hernandez
Alejandro Mohar Betancourt
Original Assignee
Psicofarma S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psicofarma S A De C V filed Critical Psicofarma S A De C V
Publication of BRPI0419032A publication Critical patent/BRPI0419032A/pt
Publication of BRPI0419032B1 publication Critical patent/BRPI0419032B1/pt
Publication of BRPI0419032B8 publication Critical patent/BRPI0419032B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçãO FARMACêUTICA DE LIBERAçãO PROLONGADA DE HIDRALAZINA E SEU USO COMO APOIO PARA O TRATAMENTO DO CáNCER. A presente invenção se refere a uma forma de liberação prolongada de hidralazina para se utilizar na terapia contra o câncer. Esta forma de liberação prolongada de hidralazina permite que se alcance no sangue uma concentração constante do princípio ativo que permite que se apresente o efeito desmetilante da hidralazina sem que apareça sua ação hipotensora, o que permite seu uso na terapia contra o câncer.
BRPI0419032A 2004-09-09 2004-09-09 composição farmacêutica de liberação prolongada de hidralazina BRPI0419032B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2004/000064 WO2006028362A1 (es) 2004-09-09 2004-09-09 Composición farmacéutica de liberación prolongada de hidralazina y su uso como apoyo para el tratamiento del cáncer

Publications (3)

Publication Number Publication Date
BRPI0419032A true BRPI0419032A (pt) 2007-12-11
BRPI0419032B1 BRPI0419032B1 (pt) 2019-02-05
BRPI0419032B8 BRPI0419032B8 (pt) 2021-05-25

Family

ID=36036613

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0419032A BRPI0419032B8 (pt) 2004-09-09 2004-09-09 composição farmacêutica de liberação prolongada de hidralazina

Country Status (17)

Country Link
US (1) US7820200B2 (pt)
EP (1) EP1803447B1 (pt)
JP (1) JP4814885B2 (pt)
CN (1) CN101039661A (pt)
BR (1) BRPI0419032B8 (pt)
CA (1) CA2579220C (pt)
CR (1) CR9035A (pt)
CY (1) CY1110508T1 (pt)
DE (1) DE602004022205D1 (pt)
DK (1) DK1803447T3 (pt)
ES (1) ES2330227T3 (pt)
MX (1) MX2007002871A (pt)
NZ (1) NZ554360A (pt)
PL (1) PL1803447T3 (pt)
PT (1) PT1803447E (pt)
SI (1) SI1803447T1 (pt)
WO (1) WO2006028362A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4521402A (en) * 1983-01-03 1985-06-04 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of hydrazine
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
HRP20010700B1 (hr) * 1999-03-31 2011-01-31 Janssen Pharmaceutica N.V. Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20050267222A1 (en) * 2002-10-22 2005-12-01 Dainippon Pharmaceutical Co. Ltd. Stabilized composition

Also Published As

Publication number Publication date
CY1110508T1 (el) 2015-04-29
US20090042889A1 (en) 2009-02-12
ES2330227T3 (es) 2009-12-07
EP1803447A1 (en) 2007-07-04
NZ554360A (en) 2009-11-27
EP1803447B1 (en) 2009-07-22
SI1803447T1 (sl) 2010-01-29
CN101039661A (zh) 2007-09-19
DE602004022205D1 (de) 2009-09-03
JP2008512450A (ja) 2008-04-24
BRPI0419032B8 (pt) 2021-05-25
CA2579220C (en) 2013-01-08
WO2006028362A1 (es) 2006-03-16
JP4814885B2 (ja) 2011-11-16
MX2007002871A (es) 2007-04-23
PL1803447T3 (pl) 2010-05-31
US7820200B2 (en) 2010-10-26
BRPI0419032B1 (pt) 2019-02-05
PT1803447E (pt) 2009-08-14
CR9035A (es) 2009-03-27
CA2579220A1 (en) 2006-03-16
DK1803447T3 (da) 2009-10-12

Similar Documents

Publication Publication Date Title
BR112014031394A8 (pt) Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral
AR047928A1 (es) Derivados de tetrahidropiridoindol
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
NZ606825A (en) Methods and compositions for treating complement-associated disorders
BRPI0923589A2 (pt) uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
BR112012029995A2 (pt) composição farmacêutica ou cosmética tópica útil para o tratamento de doenças ou condições que transcursam por meio de um déficit de maturação do envelope cornificado
AR059577A1 (es) Agente de aceleracion de absorcion del calcio
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
AR053775A1 (es) Nonadepsipeptidos acilados ii
SV2007002235A (es) Nuevos derivados de pirimidina y su uso ref. bhc041311-sv
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
EA200602002A1 (ru) Применение спинозинов для заживления ран
PE20061051A1 (es) Composicion farmaceutica que comprende mirtazapina s
BRPI0606528A2 (pt) composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/09/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2791 DE 02-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.